

Personal data

Name: Alessandro Rambaldi
Date and place of birth: 22/08/1955, Bologna, Italy
Citizenship: Italian
Work address: Hematology and Bone Marrow Transplant Unit
ASST Papa Giovanni XXIII
Piazza OMS, 1 24127 Bergamo, Italy
Phone: +39 035 2673684
FAX: +39 035 2674968
E-mail: arambaldi@asst-pg23.it



Education

1981 Medical Degree, University of Milan Italy,
1985 Board in Clinical Pharmacology, University of Milan
1991 Board in Hematology, University of Bari Italy
2005 Qualification as Associate Professor in Hematology,
2013 Qualification as Full Professor in Hematology,

Current position

Head of the Bone Marrow Transplantation Program, Ospedali Riuniti Bergamo since 1999
Head Unit of Hematology, Ospedali Riuniti Bergamo since 2006
Full Professor in Hematology, University of Milan since 2016

Scientific activity

Author of more than 490 peer review publications

Main research grants

Principal Investigator of Research Projects supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), European Community (EC), Agenzia Italiana del Farmaco (AIFA), Italian Health Ministry, NIH

- Ricerca finalizzata RF-LOM-2008-1164043: "Diagnostic and prognostic significance of PTX3 levels in pediatric and adult patients with acute leukemia"
- AIRC grant 5 x 1000 : "An integrate platform for molecular studies and clinical trials in chronic myeloproliferative neoplasms" (AGIMM) – Project code: 10005
- AIRC grant 5 x 1000: "Innate Immunity in Cancer: molecular targeting and cellular therapy" (IIC) – Project code: 9962
- AIRC: high throughput sequencing efficacy in clonality and MRD evaluation in ALL patients lacking molecular probes by ASO-QPCR (AIRC IG grant code 16105)
- Myeloproliferative Disorder Research Consortium (MPD-RC)

Member of the Board of the Italian Group Bone Marrow Transplantation (GITMO) since 2000; member of the Board of the Joint Accreditation Committee ISCT-EBMT (JACIE) since 2002; Investigator of the, funded by National Health Institute, USA

Research Interest

- Hematopoietic stem cell transplantation and new cellular therapies
- Pioneering laboratory and clinical studies in non-Hodgkin Lymphomas and acute leukemias
- Development of innovative strategies for the molecular diagnosis and pioneering risk adapted treatment strategy in adult ALL
- Chronic Myeloproliferative Neoplasms therapy